KH9702

KH9702 is a small molecule, highly selective inhibitor of the voltage-gated sodium channel Nav1.8 (SCN10A), currently under development by Chengdu Kanghong Biotech for the treatment of acute pain. Nav1.8 is a sodium channel subtype primarily expressed in peripheral nociceptive neurons, where it plays a critical role in the initiation and transmission of pain signals. By selectively blocking this channel, KH9702 aims to provide potent analgesia while avoiding the central nervous system side effects and addiction potential associated with opioids, as well as the systemic risks linked to nonsteroidal anti-inflammatory drugs (NSAIDs). The drug is formulated as an oral tablet and has entered early-stage clinical evaluation in China.